Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.

Current opinion in oncology - 1 Jun 2009

Ottmann Oliver G, Pfeifer Heike

Abstract excerpt

The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy. Treatment outcome with imatinib-based regimens has improved compared with historic controls, but most patients who do not undergo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Combined Modality Therapy
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Philadelphia Chromosome

Share to Piperazines

Share to Stem Cell Transplantation

Share to Thiazoles

Source

Identifiers

PMID: 19561414
DOI: 10.1097/01.cco.0000357476.43164.6b

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.PMID 19561414Read ↗

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).Semantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in Adults: A Broader Range of Options, Improved Outcomes, and More Therapeutic DilemmasSemantic proximity Read ↗

Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in AdultsSemantic proximity Read ↗

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome‐positive adult acute lymphoblastic leukemiaSemantic proximity Read ↗

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in ChildhoodSemantic proximity Read ↗

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic AnemiaSemantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of ChallengesSemantic proximity Read ↗

Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.